Purpose Of Review: In this review, the evolving role of currently available genomic assays for hormone receptor-positive, early-stage breast cancer in the selection of patients for extended adjuvant endocrine therapy will be discussed.
Recent Findings: Several studies have investigated the prognostic performance of the Oncotype DX, Breast Cancer Index (BCI), Prosigna, and EndoPredict genomic assays in the late recurrence setting (>5 years after diagnosis), beyond standardly used clinicopathologic parameters, with mixed results. Recently, BCI has also been validated to predict the likelihood of benefit from extended endocrine therapy, though certain data limitations may need to be addressed to justify routine use in clinical practice.
Summary: Even after 5 years of adjuvant endocrine therapy, patients with hormone receptor-positive breast cancer have a significant risk for late recurrence, including distant metastases, that might be prevented with longer durations of endocrine therapy. However, the added toxicity and variable benefit derived from extended endocrine therapy make optimal patient selection crucial. Genomic assays are in development to risk-stratify patients for late recurrence and determine efficacy of extended endocrine therapy, with the aim to help guide extended endocrine therapy decisions for clinicians and individualize treatment strategies for patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCO.0000000000000985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishment of subcutaneous transplantation platform for delivering induced pluripotent stem cell-derived insulin-producing cells.
PLoS One
January 2025
Faculty of Veterinary Science, Veterinary Clinical Stem Cell and Bioengineering Research Unit, Chulalongkorn University, Bangkok, Thailand.
Potential trend of regenerative treatment for type I diabetes has been introduced for more than a decade. However, the technologies regarding insulin-producing cell (IPC) production and transplantation are still being developed. Here, we propose the potential IPC production protocol employing mouse gingival fibroblast-derived induced pluripotent stem cells (mGF-iPSCs) as a resource and the pre-clinical approved subcutaneous IPC transplantation platform for further clinical confirmation study.
View Article and Find Full Text PDFImmune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System.
Age Ageing
January 2025
Department of Medical Oncology, Koç University Hospital, Davutpaşa Street 34010 Topkapı, Istanbul, Turkey.
Background: Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy, yet they carry a unique spectrum of immune-related adverse events (irAEs). Given the ageing global population and the underrepresentation of older adults in clinical trials for ICIs, we investigated the occurrence and characteristics of irAEs in older versus younger adults as well as among different age subsets within the older adult population.
Methods: We analysed the U.
Spatial Variation in the Association between Extreme Heat Events and Warm Season Pediatric Acute Care Utilization: A Small-Area Assessment of Multiple Health Conditions and Environmental Justice Implications in California (2005-2019).
Environ Health Perspect
January 2025
Scripps Institution of Oceanography, San Diego, California, USA.
Background: The increasing frequency and severity of extreme heat events due to climate change present unique risks to children and adolescents. There is a lack of evidence regarding how heat's impacts on pediatric patients vary spatially and how structural and sociodemographic factors drive this heterogeneity.
Objectives: We examined the association between extreme heat events and pediatric acute care utilization in California for 19 distinct health conditions.
The patient and caregiver experience of CAR T-cell therapy: A qualitative analysis.
J Psychosoc Oncol
January 2025
University of Minnesota Medical School, Minneapolis, MN, USA.
Background/purpose: Immunotherapies, such as CAR-T, have revolutionized cancer treatment for some cancers. However, these treatments often require active participation of a family member or friend to act as a caregiver at home for several weeks after infusion. Given the novelty of CAR-T, there is a need to better understand the experience of patients receiving these treatments and their caregivers.
View Article and Find Full Text PDFCorrection to: Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study.
Endocrine
January 2025
Pediatric Unit, IRCCS AOU of Bologna, Bologna, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!